CSL dan Alentis umum perkongsian global untuk membangunkan dan mengkomersialkan lixudebart bagi penyakit buah pinggang dan hati yang jarang berlaku

PartnershiplixudebartPositive

AI Analysis

Summary

CSL and Alentis Therapeutics announced a global partnership to develop and commercialize lixudebart for rare kidney and liver diseases. Alentis will receive a US$355 million upfront payment and up to US$1.2 billion in commercial milestones, with global profits shared.

Outcome Details

Alentis will receive a US$355 million upfront payment and up to US$1.2 billion in commercial milestones, with global profits shared.

Importance:7/10

Sentiment:

0.70

partnershiplicensingupfront paymentmilestonesprofit sharingrare diseasekidney diseaseliver diseaseCSLAlentis

Related Companies

$GBCMD $BMGL

Read the original article

Published by PR Newswire Pharma on October 8, 2026 4:11 AM

Read Original